Featured Research

from universities, journals, and other organizations

Stem Cells Isolated From Monkey Eggs Continue Producing Variety Of Other Cells

Date:
September 23, 2003
Source:
Wake Forest University Baptist Medical Center
Summary:
A line of monkey stem cells, produced without the use of an embryo, has reproduced for more than two years and still retains the capability of differentiating into a variety of tissue types, a research team reports in the current on-line edition of the Proceedings of the National Academy of Sciences.

WINSTON-SALEM, N.C. - A line of monkey stem cells, produced without the use of an embryo, has reproduced for more than two years and still retains the capability of differentiating into a variety of tissue types, a research team reports in the current on-line edition of the Proceedings of the National Academy of Sciences.

Kent Vrana, Ph.D., professor of physiology and pharmacology at Wake Forest University Baptist Medical Center and the first author on the report, said the stem cells have produced two types of neurons, and many other tissues such as heart, smooth muscle and beating cilia, the tiny hairlike extensions that line the airways.

The research team, from four universities and two private companies, first reported the stem cell line in January 2002 in the journal Science. At that time, some other scientists thought that the stem cell line might stop after several generations.

Vrana reports in the current paper that the stem cells possess the biological properties of indefinite replication found in cancer cells and embryonic stem cells.

These stem cells were developed by a process called parthenogenesis -- using only an egg from a female monkey and no sperm. The resulting multiplying group of cells, called a parthenote, cannot successfully implant into the mother's womb and hence cannot develop any further than what is called the blastocyst stage, essentially a ball of cells.

But the team was able to take cells from that blastocyst and begin the stem cell line, called Cyno-1. Jason Hipp, a Wake Forest graduate student and second author on the paper, said this approach could "bypass the need for creating a competent embryo for the creation of stem cells."

Of great interest is the potential for developing an unlimited number of one type of neuron. These neurons could eventually pave the way for the treatment of Parkinson's disease.

The neurons synthesize a neurotransmitter called dopamine, and are impaired in people with Parkinson's disease.

"Clinical transplantation of specific fetal neurons has shown promise in the treatment of Parkinson's and Huntington's disease," said Vrana, "but obtaining such cells from animals or human fetal brain remains problematic." Obtaining cells produced in the laboratory from stem cells that come from parthenotes "could alleviate some of the ethical and technical concerns of human cell therapy."

Vrana said the striking ability of these stem cells derived from parthenotes to differentiate suggest a valid alternative to stem cells derived from normal fertilization.

To test whether the stem cells were "pluripotent" -- able to produce any cells -- the stem cells were injected into a mouse without a functioning immune system. The cells produced all three of the body's cell layers: ectoderm (neuron, skin and hair follicles), mesoderm (cartilage, muscle and bone) and endoderm (intestinal epithelia), according to Jose Cibelli, professor of animal science at Michigan State University and co-author.

Moreover, the monkey stem cells have a normal number of chromosomes, Vrana said.

Parthenogenesis is not new biologically, but it is unknown in mammals. "Flies, ants, lizards, snakes, birds, reptiles, amphibians, honeybees and crayfish routinely reproduce in this manner. Placental mammals are not capable of this form of reproduction," said Vrana.

Among other members of the team were Ashley Goss, undergraduate student, Kathleen A. Grant, Ph.D., professor, Brian A. McCool, Ph.D., and Stephen J. Walker, Ph.D., assistant professors of physiology and pharmacology, and David Riddle, Ph.D., assistant professor of neurobiology and anatomy, all from Wake Forest; Peter Wettstein from the Department of Microbiology and Immunology at the Mayo Clinic; Lorenz Studer and Viviane Tabor from the Sloan Kettering Cancer Center in New York; Kerrianne Cunniff from Millennium Pharmaceuticals in Cambridge, Mass.; and Michael D. West and other researchers from Advanced Cell Technology in Worcester, Mass.


Story Source:

The above story is based on materials provided by Wake Forest University Baptist Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Wake Forest University Baptist Medical Center. "Stem Cells Isolated From Monkey Eggs Continue Producing Variety Of Other Cells." ScienceDaily. ScienceDaily, 23 September 2003. <www.sciencedaily.com/releases/2003/09/030923065359.htm>.
Wake Forest University Baptist Medical Center. (2003, September 23). Stem Cells Isolated From Monkey Eggs Continue Producing Variety Of Other Cells. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2003/09/030923065359.htm
Wake Forest University Baptist Medical Center. "Stem Cells Isolated From Monkey Eggs Continue Producing Variety Of Other Cells." ScienceDaily. www.sciencedaily.com/releases/2003/09/030923065359.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins